

CHAPTER ONE: INTRODUCTION	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY	1
SCOPE OF REPORT	1
METHODOLOGY AND INFORMATION SOURCES.....	2
INTENDED AUDIENCE.....	2
ANALYST CREDENTIALS.....	2
RELATED REPORTS	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY	4
<i>SUMMARY TABLE U.S. NET SALES OF ONCOTYPE AND TROFILE THROUGH 2015 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE U.S. NET SALES OF ONCOTYPE AND TROFILE 2008-2015 (\$ MILLIONS)</i>	6
 CHAPTER THREE: OVERVIEW, STRUCTURE AND SIGNIFICANCE OF THE COMPANION DIAGNOSTICS INDUSTRY	 7
COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE	7
HISTORICAL OVERVIEW.....	7
<i>TABLE 1 PERCENTAGE OF PRODUCTS IN EACH SECTOR OF THE COMPANION DIAGNOSTICS INDUSTRY (%)</i>	8
<i>FIGURE 1 PERCENTAGE OF PRODUCTS IN EACH SECTOR OF THE COMPANION DIAGNOSTICS INDUSTRY</i>	8
PERSONALIZED MEDICINE TREND OVERVIEW.....	8
<i>TABLE 2 OVERVIEW OF PERSONALIZED MEDICINE PRODUCTS</i>	9
<i>TABLE 3 PERCENTAGE OF EACH PERSONALIZED MEDICINE PRODUCT CATEGORY IN 2008 AND THEIR FORECAST, 2008 AND 2012 (%)</i>	10
<i>FIGURE 2 PERCENTAGE OF EACH PERSONALIZED MEDICINE PRODUCT CATEGORY IN 2008 AND THEIR FORECAST, 2008 AND 2012 (%)</i>	10
<i>FIGURE 2 (CONTINUED)</i>	11
<i>TABLE 4 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION, THROUGH 2015 (\$ MILLIONS)</i>	12

CURRENT PARTICIPANTS IN THE COMPANION	
DIAGNOSTICS INDUSTRY	12
<i>In Vitro</i> Diagnostics, Biomarker and Companion	
Diagnostics Companies	12
<i>In Vitro</i> Diagnostics Companies	12
Biomarker Research Companies	12
Companion Diagnostics Companies	13
Laboratory Test Services Companies (CLIA Laboratories)	13
Pharmaceutical Companies	13
Regulatory Entities, Insurance Companies and	
Healthcare Providers	14
Regulatory Entities	14
Insurance Companies	14
Healthcare Providers	15
Patients, Physicians and Public Opinion as Additional	
Drivers of the Companion Diagnostic Industry	15
Patients, Physicians and...(Continued)	16
Organizations Supporting the Personalized Medicine	
Approach	17
FIGURE 3 DRIVERS OF COMPANION DIAGNOSTICS INDUSTRY	18
CHALLENGES AND OBSTACLES TO COMPANION	
DIAGNOSTICS INDUSTRY DEVELOPMENT	18
Challenges and obstacles of...(Continued)	19
FIGURE 4 CHALLENGES OF COMPANION DIAGNOSTICS	
INDUSTRY	20
BIOMARKERS MARKET AS BASIS FOR THE COMPANION	
DIAGNOSTICS INDUSTRY	21
TABLE 5 GLOBAL BIOMARKER MARKET (\$ BILLIONS)	21
TABLE 6 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING	
TO RESEARCH AREAS IN 2008 (\$ BILLIONS)	22
CANCER BIOMARKERS	22
CARDIOVASCULAR DISEASE BIOMARKERS	22
CNS DISORDERS BIOMARKERS	23
IN VITRO DIAGNOSTICS (IVD) INDUSTRY AS A DRIVER FOR	
THE COMPANION DIAGNOSTICS FIELD	23
TABLE 7 ESTIMATE FOR MAJOR PLAYERS OF IVD COMPANIES IN	
2010 (%)	24
EFFECT OF THE REGULATORY ASPECT ON COMPANION	
DIAGNOSTICS INDUSTRY DEVELOPMENT	25
TABLE 8 COMPANION DIAGNOSTICS, ASSOCIATED DRUGS AND	
REGULATORY APPROVAL STATE	26

COMPANION DIAGNOSTICS COST AND REIMBURSEMENT	
POLICIES AS DRIVERS FOR INDUSTRY DEVELOPMENT.....	27
<i>TABLE 9 COMPANION DIAGNOSTICS COST EXAMPLES (DOLLARS).....</i>	<i>28</i>
<i>TABLE 10 EXAMPLES OF COMPANION DIAGNOSTICS EFFECT ON</i>	
<i>HEALTHCARE SAVINGS (\$ MILLIONS).....</i>	<i>29</i>
GENERAL IMPACT OF PERSONALIZED MEDICINE TREND ON	
MARKET DEVELOPMENT IN OTHER INDUSTRIES	30
<i>TABLE 11 MARKET SEGMENT ESTIMATES IN PERSONALIZED</i>	
<i>MEDICINE 2010 AND 2015 (\$ BILLIONS).....</i>	<i>30</i>
GENERAL IMPACT OF PERSONALIZED...(CONTINUED).....	31
GENERAL IMPACT OF PERSONALIZED...(CONTINUED).....	32
ADDITIONAL PERSONALIZED MEDICINE PRODUCTS ON	
THE MARKET	32
<i>TABLE 12 ADDITIONAL PERSONALIZED MEDICINE PRODUCTS ON</i>	
<i>THE MARKET FOR THE GENERAL PUBLIC (\$)</i>	<i>33</i>
Direct to Consumer Genetic Tests or At-Home Genetic	
Tests.....	33
Direct to Consumer...(Continued).....	34
Personal Genome Sequencing	35
PATENT APPLICATIONS FOR COMPANION DIAGNOSTICS AND	
BIOMARKERS	35
<i>TABLE 13 PATENT APPLICATIONS WORLDWIDE IN DIFFERENT</i>	
<i>BIOMARKER RESEARCH FIELDS, 2009-2010</i>	<i>36</i>
<i>FIGURE 5 PATENT APPLICATION WORLDWIDE IN DIFFERENT</i>	
<i>BIOMARKER RESEARCH FIELDS, 2009-2010</i>	<i>37</i>
EXAMPLES OF RECENT PATENT APPLICATIONS AND	
GRANTED PATENTS IN THE COMPANION	
DIAGNOSTICS INDUSTRY	37
Power3/StemTroniX	37
Aveo Pharmaceuticals	37
Clariant Inc.	38
Entelos	38
CURRENT TECHNIQUES AND TECHNOLOGIES FOR	
COMPANION DIAGNOSTICS	39
<i>TABLE 14 ADVANTAGES AND DISADVANTAGES OF MOST</i>	
<i>COMMON TECHNIQUES FOR COMPANION DIAGNOSTICS</i>	<i>40</i>
DIGITAL PATHOLOGY AND QUANTITATIVE	
IMMUNOSTAINING AS A NEW TREND IN COMPANION	
DIAGNOSTIC ASSAY DEVELOPMENT.....	41
NEW SCIENTIFIC APPROACHES TO COMPANION TEST	
DEVELOPMENT	42

MicroRNA (miRNA) Profiling	42
Imaging as a New Approach to Companion Diagnostics Tests.....	43
Cognitive Diagnostics as Companion Diagnostics Test.....	44
GENETIC KNOWLEDGE AND CLINICIAN OPINION AS DRIVERS FOR COMPANION DIAGNOSTICS MARKET	44
<i>TABLE 15 STATISTICS IN THE U.S. FOR PHYSICIAN OPINION REGARDING COMPANION DIAGNOSTIC TESTS AS PART OF DIAGNOSIS AND PATIENT TREATMENT (%).....</i>	45
<i>TABLE 16 CURRENT STATISTICS ON PHYSICIAN OPINION IN DIFFERENT ASPECTS OF PERSONALIZED MEDICINE IN THE U.S. (%).....</i>	45
<i>TABLE 16 (CONTINUED).....</i>	46
LIST OF COMPANION DIAGNOSTICS COMPANIES AND EVALUATION OF MARKET PARTICIPANTS.....	46
<i>TABLE 17 CURRENT MARKET PARTICIPANTS IN COMPANION DIAGNOSTICS.....</i>	47
<i>TABLE 17 (CONTINUED).....</i>	48
<i>TABLE 17 (CONTINUED).....</i>	49
<i>TABLE 17 (CONTINUED).....</i>	50
<i>TABLE 17 (CONTINUED).....</i>	51
CURRENT MARKET ANALYSIS	51
Roche Diagnostics.....	51
Qiagen	51
DAKO, Quest Diagnostics and LabCorp.....	52
Other Competitors in the Market.....	52
“Newcomers” to Companion Diagnostics Field	52
Life Technologies	53
GenProbe	53
GE Healthcare	53
Acquisitions and Partnerships Trend.....	53
Major Pharmaceutical Companies as Partners for Companion Diagnostics Companies	54
<i>TABLE 18 EXAMPLES OF PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTIC COMPANIES AND TESTS DEVELOPED BETWEEN 2007 AND 2010</i>	54
<i>TABLE 19 NUMBER AND PERCENTAGE OF DEALS IN COMPANION DIAGNOSTICS ACCORDING TO RESEARCH AREAS 2004-2008</i>	55
Failures and Lessons from Companion Diagnostics Development.....	55
Nanosphere Inc.	55

Perlegen.....	56
Sequenom	56
Companion Tests as a Strategy to Improve Drug Sales Performance.....	56
Companion Diagnostics as a Strategy for “Failing” Drugs.....	57
 CHAPTER FOUR: COMPANION DIAGNOSTICS INDUSTRY OVERVIEW	
IN DIFFERENT RESEARCH AREAS	58
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CANCER	58
OVERVIEW	58
<i>TABLE 20 COMMON COMPANION DIAGNOSTIC TESTS IN CANCER APPLICATIONS</i>	58
<i>TABLE 20 (CONTINUED)</i>	59
MAIN COMPANION DIAGNOSTICS ASSAY IN ONCOLOGY DRUG MARKET	59
Her2 Test	59
Manufacturers of Her2/neu Assay	60
Manufacturers ... (Continued).....	61
Manufacturers ... (Continued).....	62
Kirsten Ras Sarcoma (KRAS) Test	63
KRAS Test Market Participants	63
<i>TABLE 21 PRICE COMPARISON FOR DIFFERENT KRAS TEST MANUFACTURERS (DOLLARS)</i>	64
EGFR Expression Test	65
Manufacturers of EGFR Kits	65
UGT1A1 test	66
Genetic Assays for Breast Cancer Prognosis.....	67
BRCA1/2	67
Aviara Breast Cancer Index/Cancer Type ID/ Aviara MGI	68
MammaPrint.....	68
Oncotype Dx.....	69
Mammostrat.....	69
Market Analysis for Cancer Prognosis Testing.....	69
<i>TABLE 22 SALES OF ONCOTYPE DX WORLDWIDE, THROUGH 2015 (\$ MILLIONS)</i>	70
<i>FIGURE 6 SALES OF ONCOTYPE DX WORLDWIDE, THROUGH 2015 (\$ MILLIONS)</i>	70
Additional Molecular Markers and Products as Companion Diagnostics for Drug Response	71

Target GI Analysis for Erbbitux/Vectibix/Fluorouracil/Camptosar Treatments.....	71
BCR–ABL Analysis for Gleevec Treatment.....	71
Thiopurine S–methyltransferase (TPMT) Activity for Purinethol/Thioguanine/ Azathioprine Treatments.....	72
Deficiency of Dihydropyrimidine Dehydrogenase (DPD) Activity for 5–Fluorouracil.....	72
CupPrint for Chemotherapy Treatments	72
G6PD Deficiency for Elitek Treatment	73
PGx Predict for Rituximab Treatment.....	73
c–Kit for Gleevec Treatment in Stomach Cancer	73
CD33 Marker for Mylotarg Treatment	73
CD25 Marker for Ontak Therapy.....	74
SUMMARY OF COMPANION DIAGNOSTICS ONCOLOGY MARKET	74
<i>TABLE 23 MARKET SHARE FOR COMPANION DIAGNOSTICS KIT DEVELOPERS IN THE ONCOLOGY MARKET, 2010 (%).....</i>	<i>74</i>
<i>FIGURE 7 MARKET SHARE FOR COMPANION DIAGNOSTICS KIT DEVELOPERS IN ONCOLOGY MARKET, 2010 (%).....</i>	<i>75</i>
INFLUENCE OF CANCER STATISTICS, HEALTHCARE COSTS AND DRUG MARKET ON COMPANION DIAGNOSTICS DEVELOPMENT.....	75
CANCER STATISTICS OVERVIEW	75
<i>TABLE 24 TOTAL U.S. CANCER STATISTICS AS ESTIMATED BY ACS AND NCI, 2010.....</i>	<i>76</i>
Breast Cancer	76
Lung Cancer.....	76
Colorectal Cancer.....	76
Leukemia	77
HEALTHCARE COSTS AS A FACTOR FOR COMPANION DIAGNOSTICS DEVELOPMENT.....	77
<i>TABLE 25 AVERAGE ANNUAL HEALTHCARE COST FOR DIFFERENT TYPES OF CANCER IN THE U.S. AND AMOUNT SPENT ON SCIENTIFIC RESEARCH IN 2008.....</i>	<i>77</i>
KRAS Companion Diagnostics as an Example for New Health Economics Model.....	77
<i>TABLE 26 ESTIMATE FOR COST SAVINGS USING COMPANION DIAGNOSTIC TEST FOR KRAS IN COLORECTAL CANCER PATIENTS</i>	<i>78</i>

EFFECT OF DRUG MARKET ON COMPANION DIAGNOSTICS PRODUCT DEVELOPMENT	78
<i>TABLE 27 EXAMPLES OF DRUGS SALES WORLDWIDE ASSOCIATED WITH COMPANION DIAGNOSTICS TESTS ON THE MARKET (\$ BILLIONS).....</i>	<i>79</i>
Herceptin and Her2 Test.....	79
Vectibix and KRAS test.....	80
PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN THE ONCOLOGY SECTOR	80
OVERVIEW	80
<i>TABLE 28 EXAMPLES OF PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN ONCOLOGY, 2004-2009.....</i>	<i>81</i>
Qiagen/DxS and Partnerships	82
DxS/ Amgen.....	82
DxS/ Bristol–Myers Squibb/ImClone Systems	82
DxS/ Exosome Diagnostics	83
DxS/ Genzyme Corporation	83
DxS/AstraZeneca.....	83
DxS/Boehringer.....	83
Amgen/Lab21	83
Almac Diagnostics Partnerships.....	84
Almac Diagnostics/Eli Lilly	84
Almac Diagnostics/Merck KGaA and U.K. Medical Research Council	84
Abbott Diagnostics/ Pfizer.....	84
Ipsogen/ ARUP.....	84
Epigenomics/Bristol–Meyer Squibb (BMS) and J&J	85
Celera/Merck and Abbott Laboratories	85
DAKO Partnerships	85
DAKO/Genentech (Roche)	85
DAKO/OSI Pharmaceuticals and BMS.....	85
DAKO/ Genentech, OSI Pharmaceuticals and Roche	86
Roche/ Plexxikon.....	86
BioMerieux/Ipsen.....	86
NEW DEALS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND COMPANION DIAGNOSTICS IN ONCOLOGY (DURING 2010)	87
OVERVIEW	87

<i>TABLE 29 RECENT PARTNERSHIPS AND COLLABORATIONS BETWEEN PHARMA, ACADEMICS AND COMPANION DIAGNOSTICS COMPANIES DURING 2010.....</i>		<i>87</i>
Almac Diagnostics/Aeterna Zentaris		88
Althea DX/The Nicholas Conor Institute for Pediatric Cancer Research.....		88
BioMerieux/GSK.....		88
Companion Diagnostics Inc./University of Indianapolis		89
DAKO/AstraZeneca		89
DxS (Qiagen)/Pfizer		89
DxS (Qiagen)/ Johns Hopkins University (JHU)		89
Response Genetics/GSK		90
TCLand Expression/Inserm		90
Ventana Medical Systems/Clavis Pharma ASA.....		90
ANALYSIS OF PARTNERSHIPS TREND		91
CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR METABOLIC DISORDERS.....		91
OVERVIEW		91
<i>TABLE 30 COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR METABOLIC DISEASES.....</i>		<i>92</i>
Fibromax.....		92
Entelos		93
Lipomics Technologies/Tethys Bioscience		93
Biocrates –Companion Diagnostics Development.....		94
Genomas–Phyziotype System		94
LDLR/Atorvastatin.....		95
PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS/ACADEMICS IN DEVELOPMENT OF COMPANION ASSAYS FOR METABOLIC DISORDERS.....		96
OVERVIEW		96
<i>TABLE 31 PARTNERSHIPS AND COLLABORATION BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS/ACADEMICS, 2005-2010</i>		<i>96</i>
Lipomics Technologies (Tethys Bioscience)/Joslin Diabetes Center (Harvard Medical School)		96
Genomas/ University of Puerto Rico Medical Science Campus		97
deCODE Genetics/Celera Corp.		97
Siemens/LabCorp.....		97
Celgene Corp./ Agios Pharmaceuticals Inc.....		98

Biocrates/Pfizer, Altana Pharma	98
MARKET POTENTIAL FOR COMPANION DIAGNOSTICS	
TESTS IN METABOLIC DISORDERS	98
<i>TABLE 32 STATISTICS AND MARKET SIZE FOR DIABETES,</i>	
<i>HYPERCHOLESTEROLEMIA AND METABOLIC SYNDROME IN</i>	
<i>THE U.S., 2009</i>	<i>98</i>
Market Potential for Companion ... (Continued)	99
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN	
CARDIOVASCULAR DISEASES	100
OVERVIEW	100
<i>TABLE 33 ANNUAL STATISTICS FOR CARDIOVASCULAR DISEASE</i>	
<i>IN THE U.S. AND RELATED HEALTHCARE COSTS</i>	<i>100</i>
<i>TABLE 34 CURRENT EXAMPLES OF COMPANION DIAGNOSTICS</i>	
<i>ON THE MARKET FOR CARDIOVASCULAR DISEASES.....</i>	<i>101</i>
Companion Diagnostics Test for Coumadin (Warfarin).....	101
<i>TABLE 35 ANNUAL STATISTICS FOR COUMADIN TREATMENT IN</i>	
<i>THE U.S., 2010</i>	<i>101</i>
Manufacturers of Companion Diagnostics Test for	
Warfarin (Coumadin)	102
Nanosphere Inc	102
AutoGenomics	102
Osmotech/Genmark Diagnostics	103
ParagonDx.....	103
Entrogen.....	103
Kimball Genetics.....	103
Additional Companies.....	103
Market Analysis for Warfarin Test Competitors	104
Market Analysis for ... (Continued)	104
<i>TABLE 36 COMPARISON OF FOUR TESTS FOR WARFARIN</i>	
<i>SENSITIVITY BY FOUR DIFFERENT MANUFACTURERS.....</i>	<i>105</i>
Companion Diagnostics for Plavix	106
Protein C Deficiency Test for Warfarin Sensitivity	106
Drug Market Associated with Cardiovascular Companion	
Diagnostics	106
Coumadin	106
Plavix.....	107
<i>TABLE 37 NET SALES FOR PLAVIX (\$ MILLIONS).....</i>	<i>108</i>
PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS	
COMPANIES AND PHARMACEUTICALS IN	
CARDIOVASCULAR DISEASES	109

<i>TABLE 38 CURRENT PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS OR ACADEMICS IN THE CARDIOVASCULAR DISEASES SECTOR.....</i>	<i>109</i>
LABCORP/ARCA BIOPHARMA (NUVELO SUBSIDIARY)	109
<i>TABLE 39 U.S. STATISTICS FOR HEART FAILURE AND ANNUAL HEALTHCARE COST</i>	<i>110</i>
AFFOMIX CORP./UNIVERSITY OF MONTREAL PHARMACOGENOMICS CENTRE AND MONTREAL HEART INSTITUTE.....	111
CELERA CORP./DECODE GENETICS	112
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CNS DISORDERS	113
<i>TABLE 40 CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR CNS DISORDERS DRUG THERAPY.....</i>	<i>113</i>
HLA-B*1502 ALLELE TESTING	113
PHYZIOTYPE PIMS	114
CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS IN CNS DISORDERS.....	114
<i>TABLE 41 CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS IN CNS DISORDERS</i>	<i>115</i>
SALADAX BIOMEDICAL	115
CYTOX.....	115
CURIDIUM MEDICA (AVACTA COMPANY).....	116
EXONHIT	116
POPULATION DIAGNOSTICS.....	116
POWER3 MEDICAL PRODUCTS.....	117
PROTAGEN.....	117
CURRENT PARTNERSHIPS BETWEEN DIAGNOSTIC COMPANIES AND THEIR PAHRMACEUTICAL PARTNERS DEVELOPING COMPANION TESTS IN CNS DISORDERS	118
<i>TABLE 42 RECENT PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR CNS DISORDERS BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES</i>	<i>119</i>
PSYNOVA NEUROTECH (RBM)/ROCHE	119
CURIDIUM MEDICA/TAKEDA.....	120
SALADAX BIOMEDICAL/BRISTOL-MYERS SQUIBB	120
POWER3 MEDICAL PRODUCTS/STEMTRONIX	120
PROTAGEN/ GERMAN FEDERAL MINISTRY OF RESEARCH AND EDUCATION'S BIOPHARMA COMPETITION.....	121
EXONHIT/ALLERGEN	121

STATISTICS, HEALTHCARE COST AND DRUG MARKET FOR CNS DISRODERS AS AN ESTIMATE FOR COMPANION DIAGNOSTICS ASSAY DEVELOPMENT	122
<i>TABLE 43 STATISTICS AND HEALTHCARE COST OF SCHIZOPHRENIA, ALZHEIMER'S AND PARKINSON'S IN THE U.S. 2009 (\$ BILLIONS)</i>	122
<i>TABLE 44 CURRENT MARKET SIZE FOR NEURODEGENERATION DISORDERS AND SCHIZOPHRENIA IN THE U.S. (\$ BILLIONS)</i>	123
SCHIZOPHRENIA AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT.....	123
NEURODEGENERATIVE DISORDERS AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT	124
Parkinson's and Current Drug Treatment	124
<i>TABLE 45 NET SALES OF MIRAPEX AND REQUIP 2007-2009 (\$ MILLIONS)</i>	125
Alzheimer's and Current Drug Treatment	125
<i>TABLE 46 NET SALES OF NAMENDA AND ARICEPT 2007-2009 (\$ MILLIONS)</i>	126
BIOMARKER RESEARCH FOR NEURODEGENERATION AS A DRIVER FOR COMPANION DIAGNOSTICS.....	126
Alzheimer's Biomarker Trend.....	126
Alzheimer's Biomarker Trend (Continued)	127
Main CSF Biomarkers in Alzheimer's	128
A β 1-42	128
Total tau protein	128
Hyperphosphorylated tau (P-tau).....	128
Isoprostanes.....	128
Cytokines	128
Other Biomarkers	129
Parkinson's Biomarker Trend.....	129
Future Trends for Development of Companion Diagnostics for CNS Disorders	130
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS TESTS IN INFECTIOUS DISEASES	130
<i>TABLE 47 CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR INFECTIOUS DISEASES</i>	131
GENETIC TEST FOR HLA-B 5701.....	131
TROPISM FOR HIV ASSAY.....	131
<i>TABLE 48 REVENUES FROM TROFILE SALES BY MONOGRAM/LABCORP (\$ MILLIONS)</i>	132
Competitors of Trofile Assay	132

Other New Opportunities for Trofile Use.....	133
<i>TABLE 49 ENTRY INHIBITORS DRUG DISCOVERY AS NEW OPPORTUNITY FOR TROFILE ASSAY.....</i>	<i>134</i>
Selzentry as an HIV Trofile Dependent Drug	134
HIV Drug Resistance Tests	135
HIV STATISTICS AND HEALTHCARE COST AS A FACTOR FOR COMPANION DIAGNOSTICS SALES FORECAST	136
<i>TABLE 50 HIV STATISTICS AND HEALTHCARE COST IN THE U.S., 2009</i>	<i>137</i>
HIV DRUG MARKET	137
<i>TABLE 51 MARKET FOR HIV DRUGS WORLDWIDE 2010 AND 2015 (\$ BILLIONS).....</i>	<i>137</i>
CURRENT PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES.....	138
<i>TABLE 52 RECENT PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES.....</i>	<i>139</i>
MitoSciences/University of Oregon.....	139
LabCorp (Monogram Bioscience)/Pfizer /Shering Plough/Progenics/Gilead Science/Avexa.....	139
Lab21/Innogenetics.....	140
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN OTHER DISEASES	141
<i>TABLE 53 CURRENT COMPANION DIAGNOSTICS PRODUCTS IN DIFFERENT CLINICAL APPLICATIONS.....</i>	<i>141</i>
ALLOMAP GENE PROFILE.....	141
HLA TESTING	142
COMPANION DIAGNOSTICS TESTS DEVELOPMENT IN DRUG METABOLISM.....	143
Cytochrome P450 2C9 (CYP2C9)	144
NAT (N–acetyltransferase)	144
Amplichip CYP2D6/CYP2C19.....	145
SEROLOGY 7 TEST FOR IBD	145
Serology 7 Test for IBD (Continued).....	146
CHAPTER FIVE: MARKET SUMMARY	147
<i>TABLE 54 LIST OF COMPANION DIAGNOSTICS PRODUCTS ON THE MARKET MENTIONED IN THE REPORT.....</i>	<i>147</i>
<i>TABLE 54 (CONTINUED).....</i>	<i>148</i>

TABLE 55 PRODUCTS IN EACH INDUSTRY SECTOR IN THE COMPANION DIAGNOSTICS INDUSTRY (%).....	149
FIGURE 8 PRODUCTS IN EACH INDUSTRY SECTOR IN THE COMPANION DIAGNOSTICS INDUSTRY (%).....	149
TABLE 56 U.S. NET SALES OF ONCOTYPE AND TROFILE, THROUGH 2015 (\$ MILLIONS).....	150
FIGURE 9 U.S. NET SALES OF ONCOTYPE AND TROFILE 2008-2015 (\$ MILLIONS).....	150
TABLE 57 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION, THROUGH 2015 (\$ MILLIONS).....	151
FIGURE 10 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION 2010 AND 2015 (\$ MILLIONS).....	152
CHAPTER SIX SELECTED COMPANIES OVERVIEW	153
ABBOTT LABORATORIES.....	153
BIOMERIEUX SA.....	154
CELERA CORP.....	155
CLINICAL DATA INC.....	156
DAKO A/S.....	157
LABCORP.....	158
QIAGEN MANCHESTER LTD. (FORMER DXS LTD)	159
QUEST DIAGNOSTICS INC.	160
ROCHE DIAGNOSTICS (DIVISION OF ROCHE GROUP).....	161
CHAPTER SEVEN: DIRECTORY OF COMPANIES	162
DIRECTORY OF COMPANIES	162
DIRECTORY OF COMPANIES (CONTINUED).....	163
DIRECTORY OF COMPANIES (CONTINUED).....	164
DIRECTORY OF COMPANIES (CONTINUED).....	165
DIRECTORY OF COMPANIES (CONTINUED).....	166
DIRECTORY OF COMPANIES (CONTINUED).....	167
DIRECTORY OF COMPANIES (CONTINUED).....	168
DIRECTORY OF COMPANIES (CONTINUED).....	169
DIRECTORY OF COMPANIES (CONTINUED).....	170
DIRECTORY OF COMPANIES (CONTINUED).....	171
DIRECTORY OF COMPANIES (CONTINUED).....	172
DIRECTORY OF COMPANIES (CONTINUED).....	173
DIRECTORY OF COMPANIES (CONTINUED).....	174
DIRECTORY OF COMPANIES (CONTINUED).....	175